Pharmaceutical

SCDARIC-33 by Regeneron Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval

SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia.

May 17, 2024 - 04:00
SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia.
Read the original article

Tags:

Previous Article

Breaking bonds to form bonds: Rethinking the Chemistry of Cations

Next Article

Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lu...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.K. sequencing study surfaces new findings about tumor DNA

STAT+: U.K. sequencing study surfaces new findings abou...

Jan 10, 2024

GSK obtains approval in Japan for shingles vaccine

GSK obtains approval in Japan for shingles vaccine

Jun 27, 2023

STAT+: PTC Therapeutics’s PKU drug succeeds in trial, but bigger hurdles for company are ahead

STAT+: PTC Therapeutics’s PKU drug succeeds in trial, b...

May 17, 2023